Introduction {#S1}
============

The mortality rate in people with epilepsy is substantially higher than that observed in the general population, which is a matter of concern among specialists ([@B1]). In this scenario, sudden unexpected death in epilepsy (SUDEP) is a leading cause of premature mortality directly related to epilepsy ([@B2]).

Sudden unexpected death in epilepsy is defined as "sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death in patients with epilepsy, with or without evidence for a seizure, and excludes documented *Status epilepticus* (SE), in which postmortem examination does not reveal a toxicological or anatomic cause for death" ([@B3]). The fatal event is most likely provoked by functional disturbance, and researchers have proposed cardiac arrhythmia as a potential cause of SUDEP ([@B2]). Recently, clinically relevant genetic variants in cardiac arrhythmia and epilepsy have been found in a considerable number of SUDEP cases ([@B4]). Inflammation has been implicated in the pathophysiological events of both epilepsy and life-threatening ventricular arrhythmia ([@B5], [@B6]), in which the central role of the interleukin-6 (IL-6) is well recognized.

Our group was the first to describe increased levels of IL-6 in the hearts of rats with chronic epilepsy ([@B7]). Omega-3 polyunsaturated fatty acids, which are abundant in fish oil, have been described as potent anti-inflammatory agents ([@B8]). Thus, in the search for complementary therapy for epilepsy, this study was conducted to examine the potential anti-inflammatory effects of fish oil supplementation on the levels of the pro-inflammatory cytokine IL-6 in the heart of rats with chronic epilepsy.

Animals and Methods {#S2}
===================

Animals {#S2-1}
-------

Adult male Wistar rats (220--280 g) were housed under standard controlled conditions (7:00 a.m./7:00 p.m. light/dark cycle; 20--22°C; 45--55% humidity) with food and water *ad libitum*. All animal experiments were carried out in accordance with the National Institutes of Health guide for care and use of laboratory animals and approved by the Animal Care Committee of UNIFESP (CEUA 188439).

Induction of Epilepsy {#S2-2}
---------------------

Epilepsy was induced according to the procedure described previously ([@B9]). In brief, 30 min after methyl scopolamine injection (1 mg/kg, s.c.---Sigma, MO, USA), pilocarpine was administered (350 mg/kg, i.p.---Sigma, MO, USA). Animals developed SE. To terminate SE, diazepam (10 mg/kg---Cristalia, Compaz) was administered subcutaneously 3 h after SE onset. Rats evolved through the latent period to the chronic phase of the pilocarpine model. To confirm the presence of epilepsy, animals were continuously video monitored for 60 days, and spontaneous recurrent seizures observed. At the end, nine rats with epilepsy (*n* = 9) were used in the experiments.

Fish Oil Treatment {#S2-3}
------------------

Animals were randomly divided into the following groups: (1) animals treated daily with vehicle (0.009% cremophor) (control vehicle); (2) animals treated daily with 85 mg/kg fish oil (control fish oil); (3) animals with epilepsy treated daily with vehicle (epilepsy vehicle); and (4) animals with epilepsy treated with 85 mg/kg fish oil (epilepsy fish oil). During the 90-day treatment, animals received vehicle (cremophor 0.009%) or fish oil (PROEPA^®^, 85 mg/kg). A single daily dose was given *via* oral gavage between 11:00 and 12:00 a.m. Volume was adjusted according to animal weight, which was verified three times a week during the 90-day treatment period. Each fish oil capsule contained eicosapentaenoic acid (EPA), 180 mg, and docosahexaenoic acid (DHA), 120 mg. Capsule contents were dissolved in 0.009% cremophor, yielding a final concentration of 21.25 mg/ml fish oil, corresponding to 3.82 mg/ml EPA and 2.55 mg/ml DHA, and the final composition of fish oil was administered as 1 ml/250 g of body weight. Animals were killed by decapitation. Hearts were removed, and ventricles were separated and split in half (for Western blot and ELISA procedures) and then stored at −80°C until use.

Measurements of IL-6 Protein Levels {#S2-4}
-----------------------------------

One half of the ventricle was used for the Western blotting procedure, and the other half was used for the ELISA assay. For Western blot analysis, samples were prepared as previously described by Nejm et al. ([@B10]). The primary antibodies used were anti-IL-6 (Millipore-Chemicon, USA) and anti-β-actin (Sigma Aldrich, USA). ELISA assays (DuoSet ELISA, R&D Systems, Minneapolis, MN, USA) were performed following the recommendations of the manufacturer. All samples were run in duplicate, and the mean value was reported.

Statistical Analysis {#S2-5}
--------------------

Data were expressed as the mean ± standard error. Statistical analysis was performed using two-way ANOVA \[grouped as control versus experimental and by treatment (vehicle versus fish oil)\] followed by Bonferroni posttest. *p* Values of 0.05 or less were considered significant.

Results {#S3}
=======

The results of Western blot analysis showed that IL-6 levels in the heart of rats with epilepsy were substantially increased when compared with control rats \[*F*(1;12) = 54.78; *p* \< 0.0001\]. Animals with epilepsy that were treated with fish oil for an extended time exhibited a marked reduction in IL-6 levels, since an interaction effect was observed between epilepsy and fish oil treatment \[*F*(1;12) = 5.34; *p* = 0.039\], as shown in Figure [1](#F1){ref-type="fig"}.

![Immunoblot of interleukin-6 (IL-6). IL-6 levels in hearts of rats from control and epilepsy groups treated with vehicle or fish oil (85 mg/kg). The PVDF membrane was probed with anti-IL-6 antibody and re-probed with anti-β-actin. Each bar represents the mean ± SEM of the ratio IL-6/β-actin from four individual experiments (\**p* \< 0.05; \*\*\**p* \< 0.001).](fneur-08-00263-g001){#F1}

In Figure [2](#F2){ref-type="fig"}, the ELISA results corroborated the results obtained with immunoblotting analysis as increased levels of IL-6 were found in the hearts of animals with epilepsy compared with those in control rats \[*F*(1;16) = 10.26; *p* = 0.0059\]. Furthermore, the ELISA results show the effectiveness of the fish oil treatment, which reduced IL-6 levels in both control and epileptic rats \[*F*(1;16) = 6.05; *p* = 0.0264\]. There was no interaction effect between epilepsy and fish oil treatment \[*F*(1;16) = 1.06; *p* = 0.3178\].

![Interleukin-6 (IL-6) quantification by ELISA. IL-6 levels in the hearts of rats in control and epilepsy groups treated with vehicle or fish oil (85 mg/kg) for 90 days. Each bar represents mean ± SEM of five individual experiments (\**p* \< 0.05; \*\**p* \< 0.01).](fneur-08-00263-g002){#F2}

Discussion {#S4}
==========

In this rodent pilocarpine model of seizures, fish oil supplementation reduced cardiac levels of IL-6, indicating an anti-inflammatory effect of fish oil.

Consistent preclinical and clinical findings support the presence of a persistent inflammatory condition in the brain and plasma of subjects with epilepsy ([@B4], [@B6], [@B11]). Epileptic seizures often affect heart rate and rhythm, and poor seizure control is by far the major clinical risk factor for SUDEP ([@B2]). However, despite the available therapeutic arsenal, 30--40% of individuals with epilepsy have uncontrolled seizures. Studies focused on the pathological basis of epilepsy have focused on the role of inflammatory events ([@B6]). Basic and clinical studies has been described that chronic inflammatory state contribute to the pathogenesis of seizures and maintance of epilepsy ([@B6], [@B11], [@B12]). Previously, we demonstrated chronically elevated levels of the pro-inflammatory cytokine IL-6 in the ventricles of rats with seizures ([@B7]). Here, our findings support the existence of persistent inflammation in the ventricles of rats with epilepsy, which exhibited elevated levels of IL-6. Elevated circulating levels of IL-6 have been described in patients with heart failure, and these higher levels are positively correlated with the presence and duration of cardiac arrhythmias and with the severity of disease and mortality risk ([@B5], [@B13]). Taken together, there is compelling evidence that increased levels of IL-6 are deeply involved in the pathophysiological mechanisms underlying both epilepsy and cardiac diseases.

Using the pilocarpine model of epilepsy, Ferrari and colleagues in our group demonstrated that chronic treatment with fish oil promoted neuroprotection and positive plastic changes in the brain of rats with epilepsy ([@B14]). The beneficial anti-inflammatory effects of omega-3 fatty acids in chronic inflammatory diseases have been consistently documented ([@B8]). Fish oil dietary consumption is suggested as a good source of omega-3 polyunsaturated fatty acids for consumers. This study suggests that chronic oil fish supplementation has a protective anti-inflammatory effect against elevated levels of IL-6 in the heart of rats with epilepsy, but the underlying mechanisms of these effects remain unknown.

Conclusion {#S5}
==========

Our findings report the beneficial anti-inflammatory effects of long-term oil fish intake in the hearts of rats with chronic inflammation associated with epilepsy. Our results suggest the potential therapeutic value of dietary supplementation with oil fish in patients with epilepsy.
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